STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Journey Medical Corporation to Present at the Emerging Growth Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Journey Medical Corporation (NASDAQ:DERM), a commercial-stage pharmaceutical company focused on FDA-approved dermatological treatments, announced its upcoming presentation at the Emerging Growth Conference. Claude Maraoui, Co-Founder, President and CEO, will deliver a corporate overview on August 20, 2025, at 12:35 p.m. ET.

The presentation will be conducted virtually through video webcasts. Investors can access the live event by registering at emerginggrowth.com/conference, and an archived version will be available on EmergingGrowth.com and the Emerging Growth YouTube Channel.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

SCOTTSDALE, Ariz., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will present a corporate overview at the Emerging Growth Conference on Wednesday, August 20, 2025 at 12:35 p.m. ET. All sessions will be conducted virtually through video webcasts.

For more information or to register for the conference, please visit: https://emerginggrowth.com/conference/.

If attendees are unable to join the live event, an archived webcast will also be made available on EmergingGrowth.com and the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference.

About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight branded FDA-approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.

Company Contact:
Jaclyn Jaffe
(781) 652-4500
ir@jmcderm.com

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com


FAQ

When is Journey Medical (NASDAQ:DERM) presenting at the Emerging Growth Conference?

Journey Medical will present on August 20, 2025 at 12:35 p.m. ET through a virtual video webcast.

Who will be presenting for Journey Medical at the Emerging Growth Conference?

Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical, will present the corporate overview.

How can investors access Journey Medical's Emerging Growth Conference presentation?

Investors can register at emerginggrowth.com/conference for the live event, or access the archived webcast later on EmergingGrowth.com and the Emerging Growth YouTube Channel.

What is Journey Medical's (DERM) main business focus?

Journey Medical is a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for dermatological conditions.
Journey Medical Corp

NASDAQ:DERM

DERM Rankings

DERM Latest News

DERM Latest SEC Filings

DERM Stock Data

212.47M
20.47M
33.05%
32.59%
5.32%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
SCOTTSDALE